Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Authors
Keywords
VEGF, Angiogenesis, Metastasis, Resistance, Microenvironment, Personalised medicine
Journal
ANGIOGENESIS
Volume 17, Issue 3, Pages 471-494
Publisher
Springer Nature
Online
2014-02-01
DOI
10.1007/s10456-014-9420-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
- (2015) Terence C. Tang et al. NEOPLASIA
- VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis
- (2013) Benoit Beuselinck et al. ACTA ONCOLOGICA
- Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models
- (2013) Xiao-Dong Zhu et al. ANGIOGENESIS
- A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
- (2013) T. Powles et al. ANNALS OF ONCOLOGY
- Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
- (2013) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy
- (2013) N S Vasudev et al. BRITISH JOURNAL OF CANCER
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1
- (2013) Jia Lu et al. CANCER CELL
- Macrophage Regulation of Tumor Responses to Anticancer Therapies
- (2013) Michele De Palma et al. CANCER CELL
- A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs
- (2013) E. Guerin et al. CANCER RESEARCH
- The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications
- (2013) G. G. Van den Eynden et al. CANCER RESEARCH
- Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth
- (2013) Lin Cheng et al. CELL
- The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
- (2013) K. Sharpe et al. CLINICAL CANCER RESEARCH
- Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
- (2013) F. Collinson et al. CLINICAL CANCER RESEARCH
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- (2013) D. Maru et al. CLINICAL CANCER RESEARCH
- Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
- (2013) N. R. Smith et al. CLINICAL CANCER RESEARCH
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- (2013) Alfredo Carrato et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
- (2013) John P. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
- (2013) Charlotte Anderberg et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Colorectal Cancer Cells Refractory to Anti-VEGF Treatment Are Vulnerable to Glycolytic Blockade due to Persistent Impairment of Mitochondria
- (2013) J. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Differential Therapeutic Effects of Anti-VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing
- (2013) D. Alishekevitz et al. MOLECULAR CANCER THERAPEUTICS
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- Drug rechallenge and treatment beyond progression—implications for drug resistance
- (2013) Elizabeth A. Kuczynski et al. Nature Reviews Clinical Oncology
- The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
- (2013) Douglas W. McMillin et al. NATURE REVIEWS DRUG DISCOVERY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuropilin signalling in vessels, neurons and tumours
- (2013) Claudio Raimondi et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
- (2013) Krastan B. Blagoev et al. Cell Reports
- Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
- (2013) Tom Donnem et al. Cancer Medicine
- Contrasting effects of sunitinib within in vivo models of metastasis
- (2012) Jonathan C. Welti et al. ANGIOGENESIS
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
- (2012) J.-C. Soria et al. ANNALS OF ONCOLOGY
- CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis
- (2012) T. Jiang et al. BLOOD
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
- (2012) B. Sitohy et al. CANCER RESEARCH
- The histological growth pattern of colorectal cancer liver metastases has prognostic value
- (2012) Gert G. Van den Eynden et al. CLINICAL & EXPERIMENTAL METASTASIS
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
- (2012) A. W. Griffioen et al. CLINICAL CANCER RESEARCH
- Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?
- (2012) J. P. B. O'Connor et al. CLINICAL CANCER RESEARCH
- Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
- (2012) V. Moreno Garcia et al. CLINICAL CANCER RESEARCH
- Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
- (2012) A. McIntyre et al. CLINICAL CANCER RESEARCH
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- The history of adoption of hepatic resection for metastatic colorectal cancer: 1984–95
- (2012) D. Grünhagen et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
- (2012) Hope S. Rugo JOURNAL OF CLINICAL ONCOLOGY
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
- (2012) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
- (2012) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- (2012) Annamaria Rapisarda et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
- (2012) Camillo Porta et al. ONCOLOGY
- Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
- (2012) Cornelia Schuster et al. PLoS One
- Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival
- (2012) T. Gruenberger et al. SURGICAL ONCOLOGY-OXFORD
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
- (2012) José R. Rossari et al. Journal of Oncology
- A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
- (2011) R. Wong et al. ANNALS OF ONCOLOGY
- Signal transduction by vascular endothelial growth factor receptors
- (2011) Sina Koch et al. BIOCHEMICAL JOURNAL
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration
- (2011) F Fan et al. BRITISH JOURNAL OF CANCER
- Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape
- (2011) E. di Tomaso et al. CANCER RESEARCH
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
- (2011) J.-L. Li et al. CANCER RESEARCH
- Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
- (2011) G. Nardo et al. CANCER RESEARCH
- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
- (2011) Nicholas J. Robert et al. Clinical Breast Cancer
- Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2011) Katherine M. Krajewski et al. EUROPEAN UROLOGY
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
- (2011) Tina Cascone et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
- (2011) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
- (2011) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies
- (2011) Rodrigo Leite de Oliveira et al. MOLECULAR ASPECTS OF MEDICINE
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
- (2011) Sònia Tugues et al. MOLECULAR ASPECTS OF MEDICINE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- (2011) Peter Carmeliet et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs
- (2011) R. Dienstmann et al. ONCOLOGIST
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy
- (2010) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
- (2010) A A M van der Veldt et al. BRITISH JOURNAL OF CANCER
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
- (2010) Keith T. Flaherty et al. CANCER BIOLOGY & THERAPY
- CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies
- (2010) P.D. Nathan et al. CANCER BIOLOGY & THERAPY
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
- (2010) Carlos Bais et al. CELL
- Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
- (2010) Sara Van de Veire et al. CELL
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer
- (2010) Andrew R. Reynolds Dose-Response
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
- (2010) Iris Helfrich et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
- (2010) Lucia Ricci-Vitiani et al. NATURE
- Glioblastoma stem-like cells give rise to tumour endothelium
- (2010) Rong Wang et al. NATURE
- Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
- (2010) J C Welti et al. ONCOGENE
- Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT
- (2010) Laure S. Fournier et al. RADIOLOGY
- VEGF-B
- (2010) Xuri Li et al. Cell Adhesion & Migration
- The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases
- (2009) Ingrid M. E. Desar et al. ACTA ONCOLOGICA
- Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors
- (2009) Pascal Wolter et al. ACTA ONCOLOGICA
- Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT
- (2009) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
- (2009) B. Nordlinger et al. ANNALS OF ONCOLOGY
- Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
- (2009) Sonja Loges et al. CANCER CELL
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Intussusceptive microvascular growth in human glioma
- (2009) Beatrice Nico et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
- (2009) J. M. L. Ebos et al. CLINICAL CANCER RESEARCH
- Imaging glioma cell invasionin vivoreveals mechanisms of dissemination and peritumoral angiogenesis
- (2009) Frank Winkler et al. GLIA
- Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling
- (2009) Samuel A. Yousem HUMAN PATHOLOGY
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
- (2009) Yun Shin Chun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- The nuances of therapy
- (2009) Lee M. Ellis et al. NATURE
- Biomechanical regulation of blood vessel growth during tissue vascularization
- (2009) Witold W Kilarski et al. NATURE MEDICINE
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way
- (2009) Peter Carmeliet et al. Nature Reviews Clinical Oncology
- The Vascular Basement Membrane as “Soil” in Brain Metastasis
- (2009) W. Shawn Carbonell et al. PLoS One
- PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment
- (2009) Emmanuelle di Tomaso et al. PLoS One
- VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
- (2009) F. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Tumor Recovery by Angiogenic Switch from Sprouting to Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing Radiation
- (2008) Ruslan Hlushchuk et al. AMERICAN JOURNAL OF PATHOLOGY
- Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
- (2008) Yuval Shaked et al. CANCER CELL
- Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer
- (2008) Elise Langenkamp et al. CELL AND TISSUE RESEARCH
- Functional significance of VEGFR-2 on ovarian cancer cells
- (2008) Whitney A. Spannuth et al. INTERNATIONAL JOURNAL OF CANCER
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
- (2008) Olwen M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- A role for VEGF as a negative regulator of pericyte function and vessel maturation
- (2008) Joshua I. Greenberg et al. NATURE
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
- (2008) Christian Stockmann et al. NATURE
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
- (2008) T. E. Hutson et al. ONCOLOGIST
- Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
- (2008) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of myeloid cells in tumor angiogenesis and growth
- (2008) Farbod Shojaei et al. TRENDS IN CELL BIOLOGY
- VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
- (2007) W Kimryn Rathmell et al. Expert Review of Anticancer Therapy
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now